How can AI help uncover new treatments for Parkinson's disease?

Oct 18, 2018

How can AI help uncover new treatments for Parkinson's disease?

It’s been 50 years since the last treatment for Parkinson’s disease has been developed - patients are waiting too long for better treatments. We believe the application of AI holds huge potential to accelerate work towards a research breakthrough in Parkinson’s.

We believe this is possible through combining the extensive knowledge of charities, such as The Cure Parkinson’s Trust, alongside our platform - a machine intelligence technology system built to mine new knowledge. In this video, Dr. Jackie Hunter explores how we can take a different approach to solve highly specific, complex research challenges and why the UK is a fantastic hub to do it.

Tagged:

More Posts

You Might Also Like

Intern at BenevolentAI part I: meet our 2020 intern cohort

What impactful work did our interns get up to across Engineering, Data Science, ML and business operations this summer? Get to know them and their work in our tech internships blog.

Nov 26, 2020

FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI

BenevolentAI scientists first identified baricitinib as a potential treatment for COVID-19 in early February 2020 using Benevolent's AI tools and biomedical knowledge graph.

Nov 20, 2020

NeurIPS 2020: Meet the BenevolentAI team

BenevolentAI is happy to announce it is sponsoring NeurIPS 2020. Join us to hear about data diversity and ML applied drug discovery, and to learn about careers in the field.

Nov 17, 2020

Careers with Impact: 5 learnings from machine learning applied drug discovery

Last week, we brought together four of our exceptional colleagues for a panel discussion on careers in machine learning applied drug discovery. Here are some of our main takeaways:

Nov 17, 2020

Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality

Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.

Nov 13, 2020

Sir Nigel Shadbolt joins BenevolentAI as a non-executive director

BenevolentAI strengthens its Board with the appointment of AI pioneer Sir Nigel Shadbolt as Non-Executive Director.

Nov 3, 2020